“Institute for Advancing Translational Medicine in bone and Joint Diseases” (TMBJ) established

15 September 2012


One of SCM’s focus research areas is the study of the mechanism, clinical trial and discovery of Chinese medicines in treating bone and joint diseases, cancer and inflammation as well as neurodegenerative disease.  To strengthen our research on this area, SCM has proposed to the University the establishment of the “Institute for Advancing Translational Medicine in Bone and Joint Diseases” (TMBJ).

As approved by the University, TMBJ was jointly established by SCM and the Faculty of Science in September 2012, with Dean Lu Aiping as Director and Dr. Zhang Ge of Associate Director.  Comprised of scientists of different disciplines and outstanding young researchers, TMBJ is a platform for translating basic scientific findings into clinical applications that would benefit patients suffering from bone and joint diseases.  The research focuses of TMBJ are: drug targeting, drug design, drug delivery and drug synthesis.  With the concerted efforts of the researchers, it is expected that they will be able to produce important and influential research output before long.  TMBJ has won funding from inter alia the National Natural Science Foundation Council of China, University Grants Committee and HKBU for six research projects, with the total funding amounting to HK$7.4 million. 

Please click on the TMBJ website for details: http://tmbj.hkbu.edu.hk